Payment overview · 2025
General Payments
$266.35
12 reported records · 7 companies
Healthcare provider profile · identity verified
Michael E Leibowitz, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SILVER SPRING, MD · NPI 1235119447
Verified facts
What the public records show
CMS Open Payments records show Michael E Leibowitz, M.D. received $266.35 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.14 | 22.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.21 | 19.2% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $44.66 | 16.8% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $43.52 | 16.3% | 1 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $24.79 | 9.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.16 | 9.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.87 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $266.35 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.21 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.21 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $44.66 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $43.52 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.81 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.33 | 1 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM Normalized: atricure cryoice cryosphere cryoablation system |
Device | AtriCure, Inc. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| SYNERGY ABLATION SYSTEM Normalized: synergy ablation system |
Device | AtriCure, Inc. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 56 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
56 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 995 | 281 |
| Amlodipine Besylate | Amlodipine Besylate | 714 | 199 |
| Losartan Potassium | Losartan Potassium | 491 | 128 |
| Ezetimibe | Ezetimibe | 417 | 136 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 361 | 112 |
| Lisinopril | Lisinopril | 269 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 249 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 235 | 69 |
| Terazosin Hcl | Terazosin Hcl | 230 | 62 |
| Metformin Hcl | Metformin Hcl | 198 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 47 |
| Atenolol | Atenolol | 100 | 26 |
| Furosemide | Furosemide | 93 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 81 | 28 |
| Allopurinol | Allopurinol | 79 | 24 |
| Irbesartan | Irbesartan | 77 | 18 |
| Glimepiride | Glimepiride | 76 | 25 |
| Omeprazole | Omeprazole | 67 | 14 |
| Simvastatin | Simvastatin | 66 | 19 |
| Clonidine Hcl | Clonidine Hcl | 64 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 64 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 18 |
| Famotidine | Famotidine | 57 | 11 |
| Mirtazapine | Mirtazapine | 57 | 23 |
| Eliquis | Apixaban | 56 | 17 |
| Alendronate Sodium | Alendronate Sodium | 53 | 18 |
| Carvedilol | Carvedilol | 52 | 16 |
| Metformin Hcl Er | Metformin Hcl | 50 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 15 |
| Synthroid | Levothyroxine Sodium | 45 | 14 |
| Valsartan | Valsartan | 45 | 12 |
| Spironolactone | Spironolactone | 44 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 15 |
| Chlorthalidone | Chlorthalidone | 43 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 11 |
| Telmisartan | Telmisartan | 34 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | 15 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Jardiance | Empagliflozin | 31 | 17 |
| Sertraline Hcl | Sertraline Hcl | 31 | 11 |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 25 | suppressed |
| Gabapentin | Gabapentin | 25 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 21 | suppressed |
| Praluent Pen | Alirocumab | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Indapamide | Indapamide | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Klor-Con M10 | Potassium Chloride | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 12 | suppressed |
| Ambien | Zolpidem Tartrate | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $266.35 · 12 records | Novo Nordisk Inc | ATRICLIP LAA EXCLUSION SYSTEM, ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM, ELIQUIS, Hillrom - Carnation Ambulatory Monitor, INSPIRE, NURTEC ODT, OTEZLA, Ozempic, REPATHA, SYNERGY ABLATION SYSTEM, TRELEGY ELLIPTA, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error